Literature DB >> 30867672

Comparative efficacy of steroid-sparing therapies for non-infectious uveitis.

Jared E Knickelbein1, Meredith Kim1, Elvira Argon1, Robert B Nussenblatt1, Nida H Sen1.   

Abstract

INTRODUCTION: Non-infectious uveitis encompasses a group of inflammatory eye diseases that can cause irreversible vision loss if left untreated or undertreated. In cases requiring stemic treatment, a step-wise treatment approach is often employed starting with corticosteroids for severe active disease, followed by initiation of steroid-sparing therapies to maintain inflammatory control and avoid the abundant complications of long-term corticosteroid use. AREAS COVERED: We review the current high-quality evidence comparing the efficacy of various systemic steroid-sparing agents in the treatment of non-infectious uveitis. For studies to be included, they had to have a prospective, randomized, comparative design or a retrospective design including at least 100 patients. EXPERT COMMENTARY: Given the rarity of uveitis and the heterogeneity of uveitic diseases, there are few randomized controlled studies that directly compare the relative efficacy of the various steroid-sparing immunosuppressive agents. Therefore, current treatment strategies are based mainly on data from observational series.

Entities:  

Keywords:  Non-infectious uveitis; adalimumab; azathioprine; cyclosporine; immunosuppression; infliximab; methotrexate; mofetil; mycophenolate

Year:  2017        PMID: 30867672      PMCID: PMC6411306          DOI: 10.1080/17469899.2017.1319762

Source DB:  PubMed          Journal:  Expert Rev Ophthalmol        ISSN: 1746-9899


  30 in total

Review 1.  Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel.

Authors:  D A Jabs; J T Rosenbaum; C S Foster; G N Holland; G J Jaffe; J S Louie; R B Nussenblatt; E R Stiehm; H Tessler; R N Van Gelder; S M Whitcup; D Yocum
Journal:  Am J Ophthalmol       Date:  2000-10       Impact factor: 5.258

Review 2.  Immunomodulatory therapy for the treatment of ocular inflammatory disease: evidence-based medicine recommendations for use.

Authors:  Eva Christina Kim; C Stephen Foster
Journal:  Int Ophthalmol Clin       Date:  2006

3.  Clinical and experimental observation on the use of ACTH and cortisone in ocular inflammatory disease.

Authors:  A C WOODS
Journal:  Am J Ophthalmol       Date:  1950-09       Impact factor: 5.258

4.  Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis.

Authors:  Conor C Murphy; Kathrin Greiner; Jarka Plskova; Linda Duncan; N Andrew Frost; John V Forrester; Andrew D Dick
Journal:  Arch Ophthalmol       Date:  2005-05

5.  Mycophenolate mofetil for the treatment of uveitis.

Authors:  Stephen C Teoh; Aideen C Hogan; Andrew D Dick; Richard W J Lee
Journal:  Am J Ophthalmol       Date:  2008-05-02       Impact factor: 5.258

6.  Azathioprine for ocular inflammatory diseases.

Authors:  Sirichai Pasadhika; John H Kempen; Craig W Newcomb; Teresa L Liesegang; Siddharth S Pujari; James T Rosenbaum; Jennifer E Thorne; C Stephen Foster; Douglas A Jabs; Grace A Levy-Clarke; Robert B Nussenblatt; Eric B Suhler
Journal:  Am J Ophthalmol       Date:  2009-07-01       Impact factor: 5.258

7.  Comparison of antimetabolite drugs as corticosteroid-sparing therapy for noninfectious ocular inflammation.

Authors:  Anat Galor; Douglas A Jabs; Henry A Leder; Sanjay R Kedhar; James P Dunn; George B Peters; Jennifer E Thorne
Journal:  Ophthalmology       Date:  2008-06-25       Impact factor: 12.079

8.  Long-term efficacy and tolerance of tacrolimus for the treatment of uveitis.

Authors:  Aideen C Hogan; Clara E McAvoy; Andrew D Dick; Richard W J Lee
Journal:  Ophthalmology       Date:  2007-05       Impact factor: 12.079

9.  Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis.

Authors:  R B Nussenblatt; A G Palestine; C C Chan; G Stevens; S D Mellow; S B Green
Journal:  Am J Ophthalmol       Date:  1991-08-15       Impact factor: 5.258

10.  Methods for identifying long-term adverse effects of treatment in patients with eye diseases: the Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study.

Authors:  John H Kempen; Ebenezer Daniel; Sapna Gangaputra; Kurt Dreger; Douglas A Jabs; R Oktay Kaçmaz; Siddharth S Pujari; Fahd Anzaar; C Stephen Foster; Kathy J Helzlsouer; Grace A Levy-Clarke; Robert B Nussenblatt; Teresa Liesegang; James T Rosenbaum; Eric B Suhler
Journal:  Ophthalmic Epidemiol       Date:  2008 Jan-Feb       Impact factor: 1.648

View more
  2 in total

1.  Antimetabolite Drugs Exhibit Distinctive Immunomodulatory Mechanisms and Effects on the Intestinal Microbiota in Experimental Autoimmune Uveitis.

Authors:  Victor Llorenç; Yukiko Nakamura; Christina Metea; Lisa Karstens; Blanca Molins; Phoebe Lin
Journal:  Invest Ophthalmol Vis Sci       Date:  2022-03-02       Impact factor: 4.799

2.  A Network of Serum Proteins Predict the Need for Systemic Immunomodulatory Therapy at Diagnosis in Noninfectious Uveitis.

Authors:  Jonas J W Kuiper; Fleurieke H Verhagen; Sanne Hiddingh; Roos A W Wennink; Anna M Hansen; Kerry A Casey; Imo E Hoefer; Saskia Haitjema; Julia Drylewicz; Mehmet Yakin; H Nida Sen; Timothy R D J Radstake; Joke H de Boer
Journal:  Ophthalmol Sci       Date:  2022-05-31
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.